She has served as lead investigator and author for trials investigating novel nutrient-stimulated hormone (NuSH)-based therapies for obesity including dual hormone receptor agonist, tirzepatide, a GIP/GLP-1 receptor agonist (Jastreboff, et al ., NEJM , 2022 and NEJM , 2024), triple hormone receptor agonist, retatrutide, a GIP/GLP-1/Glucagon receptor agonist (Jastreboff, et al ., NEJM , 2023), and a monthly monoclonal antibody peptide conjugate, maridebart cafraglutide, a GIP receptor antagonist GLP-1 receptor agonist (Jastreboff, et, al., NEJM, 2025)
References Sikiric P, Seiwerth S, et al
Likewise, some hypothesize that low testosterone in women influences libido
It is a newer medication that targets not one, but two different hormones in your body, which may make it little more effective for weight loss than Semaglutide
|back to table of contents| |top of section| |top of page| C